Top 10 Biotech Companies 2004: Innovators and Leaders in the Market
New visiongain report
More than 325 million people worldwide have been helped by the more than 130
biotechnology drugs and vaccines approved by the US FDA. Of the biotech
medicines on the market, 70 per cent were approved in the last six years.
Market capitalization of the biotech industry was $224 billion in 2002 and
the industry has more than tripled in size since 1992, with revenues
increasing from $8 billion in 1992 to $27.6 billion in 2001. Biotechnology
is one of the most research-intensive industries in the world. The U.S.
biotech industry spent $15.6 billion on research and development in 2001.
The life sciences hold considerable promise as an investment sector. In
recent years biotech has established itself as a successful industry in its
own right, with a number of high profile approvals by leading companies
contributing to the profile of the industry.
Visiongain’s Top 10 Biotech Companies 2004 assesses the impact of the
leading companies in this industry. Included in this report is detailed
information concerning various facets of the companies’ business,
highlighting their reasons for success in the marketplace. The following
information is provided:
• Key product sales and forecasts
• Research and development highlights
• Reasons for Success
• Key licensing agreements
• Total revenue
• Royalties and licensing revenue
• Operating expenses
• Research and development expenses
• Merger/acquisition status
• Total assets
Other key financial figures and company background information are also
provided.
From the standpoint of growth of Earnings Per Share (EPS), the leading five
biotechs outperformed the leading five pharmaceutical companies. When we
take into account the fact that the future of the global pharmaceutical
industry is suffering from a developmental 'dry spell' where their product
pipelines are concerned, the role of biotech is becoming increasingly
prominent in their future. This report provides valuable information and
analysis for biotech companies, pharma leaders, and venture capitalists who
wish to benchmark the leaders in the field and better understand why some
companies succeed and some fail. Order this report today.
Below are the full table of contents:
Table of Contents - Top 10 Biotech Companies 2004: Innovators and Leaders
in the Market
1 Introduction and Methodology
1.1 The State of the Biotechnology Industry in 2003
1.2 Some Important Facts About the Biotechnology Industry
Table 1.1 The Rise of the Biotech Industry: Revenue and R&D 1992-2001
Graph 1.1 Biopharmaceutical Sales Growth 1992-2001
Graph 1.2 New Biotech Drug Approvals 1992-2001
1.3 The Rise of Biotechnology in the 20th Century: A Timeline
1.4 Valuing the Biotech Market in 2003
Graph 1.3 Average Value of Biotech Alliance by Developmental Stage
Table 1.2 Average Value of Biotech Alliance by Developmental Stage
Graph 1.4 Investment in US Life Sciences 1995 - 2002
Table 1.3 Investment in US Life Sciences 1995 - 2002
1.5 Report Format
1.6 Research Methodology
2 Amgen
2.1 Overview of Business
2.2 Corporate History
2.3 Employees
2.4 Headquarters and Year Established
2.5 U.S. Exchange Ticker Symbol
2.6 Historical Stock Prices
Graph 2.1 Amgen’s Historical Stock Prices Jan 2003 to Nov 2003
2.7 Key Financial Information
2.7.1 Product Sales
Graph 2.2 Amgen Product Sales 1999-2002
2.7.2 Corporate Partner Revenues
Graph 2.3 Amgen Corporate Partner Revenues 2000-2002
2.7.3 Royalty Income
Graph 2.4 Amgen Royalty Revenues 2000-2002
2.7.4 Revenues
Graph 2.5 Amgen Revenues 1999-2002
Table 2.1 Total Amgen Revenues, by Geographic Region 2000-2002
Graph 2.6 Total Amgen Revenues, by Geographic Region 2002
2.7.5 Total Operating Expenses
2.7.6 Research and Development Expenses
2.7.7 Assets
Graph 2.7 Amgen Total Assets 2000-2002
2.7.8 Net Income/Net Loss
Graph 2.8 Amgen Adjusted Net Income 1999-2002
2.7.9 Stockholders' Equity
2.7.10 Earnings/Loss per Share
2.8 The Acquisition of Immunex and it's Ramifications
Table 2.2 Peak Revenues Forecast for Enbrel 2002-2005
Graph 2.9 Peak Revenues for Amgen's Enbrel 2002-2005
2.9 Key Therapeutic Areas
2.10 Leading Prescription Drug Products in the Amgen Portfolio
Graph 2.10 Amgen's Share of the Biopharmaceutical Market 2002
2.10.1 Epogen
Graph 2.11 Global Sales of Epogen 2000-2002
2.10.2 Aranesp
Graph 2.12 Global Sales of Aranesp 2001-2002
2.10.3 Neulasta
2.10.4 Neupogen
Graph 2.13 Global Sales of Neupogen 2000-2002
2.10.5 Enbrel
2.11 Joint Ventures/Alliances
2.11.1 Royalties
2.12 Research and Development
2.12.1 Highlights
Graph 2.14 Amgen R & D Expenses 1999-2002
Table 2.3 Amgen's Hematology and Oncology Pipeline
Table 2.4 Amgen's Bone and Inflammation Pipeline
Table 2.5 Amgen's Neurology and Endocrinology Pipeline
2.13 Reasons for Success
3 Genentech
3.1 Overview of Business
3.2 Corporate History
3.3 Employees
3.4 Headquarters and Year Established
3.5 U.S. Exchange Ticker Symbol
3.6 Historical Stock Prices
Graph 3.1 Genentech’s Historical Stock Prices Jan 2003 to Nov 2003
3.7 Key Financial Information
3.7.1 Product Sales
Graph 3.2 Genentech's Product Sales 2000-2002
3.7.2 Corporate Partner Revenues
Graph 3.3 Genentech's Collaborative Profit Sharing 2000-2002
3.7.3 Royalty Income
Graph 3.4 Genentech's Royalties Income 2000-2002
3.7.4 Revenues
Graph 3.5 Genentech's Total Revenues 2000-2002
3.7.5 Total Operating Expenses
Graph 3.6 Genentech's Total Costs and Expenses 2000-2002
3.7.6 Research and Development Expenses
Graph 3.7 Genentech's Research and Development Expenses 2000-2002
Graph 3.8 Genentech's R&D Expense as a percentage of revenue 2000-2002
3.7.7 Assets
Graph 3.9 Genentech's Total Assets 2000-2002
3.7.8 Net Income (Loss)
Graph 3.10 Genentech's Net Income (Loss) 2000-2002
3.7.9 Stockholders' Equity
3.7.10 Earnings/Loss per Share
3.8 Key Therapeutic Areas
3.8.1 Oncology
3.8.2 Immunology
Graph 3.11 Financial Forecast for Genentech's Immunology Portfolio
2004-2009
3.8.3 Vascular Medicine
3.8.4 Growth Hormone Products
3.9 Leading Prescription Drug Products in the Genentech Portfolio
Table 3.1 Genentech's Product Sales 2000-2002 ($ mn)
Graph 3.12 Genentech's Total Product Sales 2000-2002
Table 3.2 Genentech's Product Sales 2002-2003 (through 3rd Quarter)
3.9.1 Rituxan
Table 3.3 Genentech’s Global Sales of Rituxan 2000-2003
Graph 3.13 Genentech’s Global Sales of Rituxan 2000-2003
3.9.2 Herceptin
Graph 3.14 Genentech’s Global Sales of Herceptin 2000-2002
3.9.3 Growth Hormone Products
Graph 3.15 Genentech’s Global Sales of Growth Hormone Products 2000-2003
3.9.4 Thrombolytics
3.10 Joint Ventures/Alliances
3.11 Research and Development
Table 3.4 Genentech’s Oncology Pipeline
Table 3.5 Genentech’s Immunology Pipeline
Table 3.6 Genentech’s Vascular Medicine Pipeline
Table 3.7 Other Drugs in Genentech’s Pipeline
3.11.1 Highlights
3.12 Reasons for Success
4 Biogen Idec
4.1 Overview of Business
4.2 Corporate Histories
4.3 Employees
4.4 Headquarters and Year Established
4.5 U.S. Exchange Ticker Symbol
4.6 Historical Stock Prices
Graph 4.1 Biogen Idec’s Historical Stock Prices Jan 2003 to Nov 2003
4.7 Key Financial Information
4.7.1 Product Sales
Graph 4.2 Biogen’s Product Sales 1998-2002
Table 4.1 Idec’s Product Sales 1998-2002
4.7.2 Corporate Partner Revenues
Graph 4.3 Idec’s Revenues from Unconsolidated Joint Business Arrangements
1998-2002
4.7.3 Royalty Income
Graph 4.4 Biogen’s Royalty Revenues 2000-2002
4.7.4 Total Revenues
Graph 4.5 Biogen’s Total Revenues 1998-2002
Graph 4.6 Idec’s Total Revenues 1998-2002
4.7.5 Total Operating Expenses
Graph 4.7 Biogen’s Total Costs and Expenses 2000-2002
Graph 4.8 Idec’s Total Costs and Expenses 2000-2002
4.7.6 Research and Development Expenses
Graph 4.9 Biogen’s Research and Development Expenses 2000-2002
Graph 4.10 Idec’s Research and Development Expenses 1998-2002
4.7.7 Assets
Table 4.2 Biogen Idec’s Total Current Assets 2002-2003
4.7.8 Net Income (Loss)
Graph 4.11 Biogen’s Net Income 2000-2002
Graph 4.12 Idec’s Net Income 1998-2002
4.7.9 Stockholders' Equity
4.7.10 Earnings/Loss per Share
4.8 Key Therapeutic Areas
4.8.1 Oncology
4.8.2 Immunology
4.9 Leading Prescription Drug Products in the Biogen IDEC Portfolio
4.9.1 Avonex
4.9.1.1 Revenues
4.9.1.2 Market Competition
Graph 4.13 Multiple Sclerosis Therapy Market Share Leaders 2002-2003
Graph 4.14 Anticipated Market Share for MS Therapies 2003
Table 4.3 Future Sales of Avonex
4.9.2 Amevive
4.9.2.1 Clinical Efficacy
4.9.2.2 Market Entrance and Competition
4.9.2.3 Revenues
4.9.2.4 Amevive's First Year on the Market: Did it Meet Expectations
4.9.2.5 Amevive's Troubles in Europe
4.9.2.6 The Future Value of Amevive
Table 4.4 Projected Sales of Amevive 2003-2009
Graph 4.15 Future Sales of Amevive
4.9.3 Rituxan
Graph 4.16 Global Sales of Rituxan 1998-2007
Table 4.5 Revenue from Unconsolidated Joint Business Arrangements
4.9.4 Zevalin
Table 4.6 Global Sales of Zevalin 2002-2003
4.10 Joint Ventures/Alliances
4.10.1 Royalties
4.11 Research and Development
Table 4.7 Biogen Idec’s Oncology Pipeline
Table 4.8 Biogen Idec’s Immunology Pipeline
4.11.1 Highlights
4.12 Reasons for Success
5 Serono
5.1 Overview of Business
5.2 Employees
5.3 Headquarters and Year Established
5.4 U.S. Exchange Ticker Symbol
5.5 Historical Stock Prices
Graph 5.1 Serono’s Historical Stock Prices Jan 2003 to Nov 2003
5.6 Key Financial Information
5.6.1 Product Sales
Graph 5.2 Serono’s Global Product Sales 1998-2002
Graph 5.3 Serono’s Global Product Sales, by Region 2002
5.6.2 Royalty and License Income
Graph 5.4 Serono’s Royalty and License Income 1998-2002
5.6.3 Total Revenues
Graph 5.5 Serono’s Total Revenues 1998-2002
5.6.4 Total Operating Expenses
Graph 5.6 Serono’s Operating Expenses 1998-2002
5.6.5 Research and Development Expenses
Graph 5.7 Serono’s Research and Development Expenses 1998-2002
5.6.6 Assets
Graph 5.8 Serono’s Total Assets 1998-2002
5.6.7 Net Income (Loss)
Graph 5.9 Serono’s Net Income 1998-2002
5.6.8 Stockholders' Equity
Graph 5.10 Serono’s Stockholders’ Equity 1998-2002
5.6.9 Earnings/Loss per Share
Graph 5.11 Serono’s Earnings (Loss) per Share 1998-2002
5.7 Key Therapeutic Areas
5.7.1 Reproductive Health
Graph 5.12 Serono’s Global Sales of Reproductive Health Products 2000-2002
5.7.2 Neurology
Graph 5.13 Serono’s Global Sales of Neurological Products 2000-2002
5.7.3 Growth and Metabolism
Graph 5.14 Serono’s Global Sales of Growth and Metabolism Products
2000-2002
5.8 Leading Prescription Drug Products in the Serono Portfolio
5.8.1 Gonal-F
5.8.1.1 Clinical Efficacy
5.8.1.2 Revenues
Table 5.1 Serono’s Global Sales of Gonal-F 2001-2003
Graph 5.15 Serono’s Global Sales of Gonal-F 2001-2003
5.8.1.3 Market Competition
Graph 5.16 Infertility Agents World Market Share 2002
5.8.2 Rebif
5.8.2.1 Clinical Efficacy
5.8.2.2 Market Entrance and Competition
5.8.2.3 Revenues
Graph 5.17 The Future Value of Rebif Worldwide 2002-2009
5.9 Joint Ventures/Alliances
5.9.1 Royalties
5.10 Research and Development
Table 5.18 Serono’s Reproductive Health Pipeline
Table 5.19 Serono’s Neurology Pipeline
Table 5.20 Serono’s Autoimmune Disease
Table 5.21 Serono’s Metabolic Pipeline
Table 5.22 Serono’s Psoriasis Pipeline
5.10.1 Highlights
5.10.1.1 Raptiva
5.10.1.2 Cladribine
5.10.1.3 Onercept
5.10.1.4 Breaker Peptides
5.11 Reasons for Success
6 Genzyme
6.1 Overview of Business
6.2 Corporate History Timeline
6.3 Employees
6.4 Headquarters and Year Established
6.5 U.S. Exchange Ticker Symbol
6.6 Historical Stock Prices
Graph 6.1 Genzyme’s Historical Stock Prices Jan 2003 to Nov 2003
6.7 Key Financial Information
6.7.1 Product Sales
Graph 6.2 Genzyme’s Global Product Sales 1998-2002
6.7.2 Total Revenues
Graph 6.3 Genzyme’s Total Revenue 1998-2002
6.7.3 Total Operating Expenses
Graph 6.4 Genzyme’s Operating Costs and Expenses 2000-2002
6.7.4 Research and Development Expenses
Graph 6.5 Genzyme’s Research and Development Expenses 2000-2002
6.7.5 Assets
6.7.6 Net Income (Loss)
6.7.7 Stockholders' Equity
6.7.8 Earnings/Loss per Share
6.8 Key Product Areas
6.8.1 Genzyme General
Graph 6.6 Genzyme General’s Total Revenue 2000-2002
6.8.1.1 Therapeutics
Table 6.1 Genzyme’s Therapeutic Products
Graph 6.7 Genzyme’s Therapeutic Sales 2000-2002
6.8.1.2 Renal
Graph 6.8 Genzyme’s Renal Product Sales 2000-2002
6.8.1.3 Diagnostic Products
Graph 6.9 Genzyme’s Sales of Diagnostic Products 2000-2002
6.8.2 Genzyme Biosurgery
Graph 6.10 Genzyme’s Biosurgery Sales 2000-2002
6.8.2.1 Orthopaedics
Graph 6.11 Genzyme’s Orthopaedics Sales 2000-2002
Table 6.2 Genzyme’s Biosurgical Specialty Products
Graph 6.12 Genzyme’s Sales of Biosurgical Specialty Products 2000-2002
6.8.2.2 Biosurgical Specialties
6.8.2.3 Cardiothoracic
Graph 6.13 Genzyme’s Sales of Cardiothoracic Products 2000-2002
6.9 Leading Prescription Drug Products in the Genzyme Portfolio
6.9.1 Cerezyme Enzyme
Graph 6.14 Sales of Cerezyme Enzyme 2000-2002
6.9.1.1 Clinical Efficacy
6.9.1.2 Revenues
6.9.1.3 Market Competition
6.9.2 Renal Drugs
6.9.2.1 Clinical Efficacy
6.9.2.2 Revenues
6.9.3 Genzyme Biosurgery
6.10 The SangStat Acquisition
6.11 Select Research and Development Projects
Table 6.3 Genzyme’s Pipeline for Lysosomal Storage Disorders
Table 6.4 Genzyme’s Endocrinology Pipeline
Table 6.5 Genzyme’s Immune-Mediated Diseases Pipeline
Table 6.6 Genzyme’s Orthopaedics Pipeline
Table 6.7 Genzyme’s Cardiovascular Pipeline
Table 6.8 Genzyme’s Cancer Vaccine Pipeline
6.11.1 Highlights
6.12 Reasons for Success
7 Chiron
7.1 Overview of Business
7.2 Corporate History Timeline
7.3 Employees
7.4 Headquarters and Year Established
7.5 U.S. Exchange Ticker Symbol
7.6 Historical Stock Prices
Graph 7.1 Chiron’s Historical Stock Prices Jan 2003 to Nov 2003
7.7 Key Financial Information
7.7.1 Product Sales
Graph 7.2 Chiron’s Product Sales 2000-2002
7.7.2 Collaborative Agreement Revenue
Graph 7.3 Chiron’s Collaborative Agreement Revenue 2000-2002
7.7.3 Royalty and License Income
Graph 7.4 Chiron’s Royalty and License Revenue 2000-2002
7.7.4 Total Revenues
Graph 7.5 Chiron’s Total Revenue 1998-2002
7.7.5 Total Operating Expenses
Graph 7.6 Chiron’s Total Operating Expenses 2000-2002
7.7.6 Research and Development Expenses
Graph 7.7 Chiron’s Research and Development Expenses 2000-2002
7.7.7 Assets
Graph 7.8 Chiron’s Total Assets 1998-2002
7.7.8 Net Income (Loss)
Graph 7.9 Chiron’s Net Income 2000-2002
7.7.9 Stockholders' Equity
7.7.10 Earnings/Loss per Share
7.8 Chiron's Businesses
Graph 7.10 Chiron’s Total Product Revenue, by Business
7.8.1 Biopharmaceuticals
Graph 7.11 Chiron’s Worldwide Sales of Biopharmaceuticals 2000-2002
7.8.2 Vaccines
Graph 7.12 Chiron’s Vaccine Revenue, by Type 2002
Graph 7.13 Chiron’s Vaccine Sales 2000-2002
7.8.3 Blood Testing
Graph 7.14 Chiron’s Blood Testing Segment Revenues 2000-2002
7.9 Leading Prescription Drug Products in the Chiron Portfolio
7.9.1 Betaseron
7.9.1.1 New Formulation for Betaseron
7.9.1.2 Clinical Efficacy
7.9.1.3 Revenues
Graph 7.15 Chiron’s Sales of Betaseron 2000-2002
7.9.1.4 Market Competition
Graph 7.16 The Future of the Multiple Sclerosis Market 2002-2009
7.9.2 Other Products Sales
7.9.2.1 TOBI
7.9.2.2 Proleukin
7.10 Joint Ventures/Alliances
7.11 Research and Development
Table 7.1 Chiron’s Biopharmaceutical Pipeline
Table 7.2 Chiron’s Vaccine Pipeline
Table 7.3 Chiron’s Blood Testing Pipeline
7.11.1 Highlights
7.11.1.1 Proleukin
7.11.1.2 HIV Vaccine
7.12 Reasons for Success
8 MedImmune
8.1 Overview of Business
8.2 Corporate History Timeline
8.3 Employees
8.4 Headquarters and Year Established
8.5 U.S. Exchange Ticker Symbol
8.6 Historical Stock Prices
Graph 8.1 MedImmune’s Historical Stock Prices Jan 2003 to Nov 2003
8.7 Key Financial Information
8.7.1 Product Sales
Graph 8.2 MedImmune’s Total Product Sales 2001-2002
8.7.2 Total Revenues
Graph 8.3 MedImmune’s Total Revenue 1998-2002
8.7.3 Total Operating Expenses
Graph 8.4 MedImmune’s Total Operating Expenses 2000-2002
8.7.4 Research and Development Expenses
Graph 8.5 MedImmune’s Research and Development Expenses 2000-2002
8.7.5 Assets
Graph 8.6 MedImmune’s Total Assets 1998-2002
8.7.6 Net Income (Loss)
Graph 8.7 MedImmune’s Net Earnings 1998-2002
8.7.7 Stockholders' Equity
Graph 8.8 MedImmune’s Stockholders’ Equity 1998-2002
8.7.8 Earnings/Loss per Share
8.8 MedImmune's Marketed Products
8.8.1 Synagis
8.8.1.1 Clinical Efficacy
8.8.1.2 Revenues
Graph 8.9 MedImmune’s Sales of Synagis 2001-2002
8.8.1.3 Market Competition
8.8.2 FluMist
8.8.2.1 Revenue
8.8.3 Ethyol
Graph 8.10 MedImmune’s Sales of Ethyol 2001-2002
Table 8.1 MedImmune’s Pharmaceutical Pipeline
8.8.4 CytoGam
8.8.5 NeuTrexin
8.8.6 RespiGam
8.9 Joint Ventures/Alliances/Royalties
8.10 Research and Development
8.10.1 Highlights
8.11 Reasons for Success
9 Cephalon
9.1 Overview of Business
9.2 Employees
9.3 Headquarters and Year Established
9.4 U.S. Exchange Ticker Symbol
9.5 Historical Stock Prices
Graph 9.1 Cephalon’s Historical Stock Prices Jan 2003 to Nov 2003
9.6 Key Financial Information
9.6.1 Product Sales
Graph 9.2 Cephalon’s Product Sales 1999-2002
9.6.2 Collaborative Agreement Revenue
Graph 9.3 Cephalon’s Collaborative Agreement Revenue 1999-2002
9.6.3 Total Revenues
Graph 9.4 Cephalon’s Total Revenue 1999-2002
9.6.4 Total Operating Expenses
Graph 9.5 Cephalon’s Total Operating Expenses 2000-2002
9.6.5 Research and Development Expenses
Graph 9.6 Cephalon’s Research and Development Expenses 2001-2002
9.6.6 Assets
Graph 9.7 Cephalon’s Total Assets 1999-2002
9.6.7 Net Income (Loss)
Graph 9.8 Cephalon’s Net Income (Loss) 1999-2002
9.6.8 Stockholders' Equity
Graph 9.9 Cephalon’s Stockholders’ Equity 1999-2002
9.6.9 Earnings/Loss per Share
9.7 Prescription Drug Products in the Portfolio
Table 9.1 Cephalon’s Key Products on European and American Markets
9.8 Cephalon's Key Money-Making Products
9.8.1 Provigil
Graph 9.10 Cephalon’s Sales of Provigil 2000-2002
9.8.2 Actiq
Graph 9.11 Cephalon’s Sales of Actiq 2000-2002
9.8.3 Gabitril
Graph 9.12 Cephalon’s Sales of Gabitril 2000-2002
9.9 The CIMA Labs Merger
9.10 Research and Development
Table 9.2 Cephalon’s Pharmaceutical Pipeline
9.10.1 Highlights
9.11 Reasons for Success
10 Gilead
10.1 Overview of Business
10.2 Corporate History Timeline
10.3 Employees
10.4 Headquarters and Year Established
10.5 U.S. Exchange Ticker Symbol
10.6 Historical Stock Prices
Graph 10.1 Gilead’s Historical Stock Prices Jan 2003 to Nov 2003
10.7 Key Financial Information
10.7.1 Product Sales
Graph 10.2 Gilead’s Product Sales 2000-2002
10.7.2 Royalty and Contract Revenue
Graph 10.3 Gilead’s Royalty and Contract Revenue 2000-2002
10.7.3 Total Revenues
Graph 10.4 Gilead’s Total Revenues
10.7.4 Total Operating Expenses
Graph 10.5 Gilead’s Total Operating Expenses
10.7.5 Research and Development Expenses
Graph 10.6 Gilead’s Research and Development Expenses
10.7.6 Assets
Graph 10.7 Gilead’s Total Current Assets 2001-2002
10.7.7 Net Income (Loss)
Graph 10.8 Gilead’s Net Income (Loss) 2000-2002
10.7.8 Stockholders' Equity
Graph 10.9 Gilead’s Total Stockholders’ Equity 2001-2002
10.7.9 Earnings/Loss per Share
Graph 10.10 Gilead’s Net Income (Loss) per Share 2000-2002
10.8 Leading Prescription Drug Products in the Portfolio
10.8.1 Viread
Graph 10.11 Gilead’s Sales of Viread 2001-2002
10.8.2 AmBisome
Graph 10.12 Gilead’s Sales of AmBisome 2001-2002
10.9 Gilead's Other Products
10.9.1 Hepsera
10.9.2 Emtriva
10.9.3 Tamiflu
10.9.4 Vistide
10.9.5 DaunoXome
10.10 Joint Ventures/Alliances
10.11 Research and Development
Table 10.1 Gilead’s Pharmaceutical Pipeline
10.11.1 Highlights
10.12 Reasons for Success
11 Millennium
11.1 Overview of Business
11.2 Corporate History Timeline
11.3 Employees
11.4 Headquarters and Year Established
11.5 U.S. Exchange Ticker Symbol
11.6 Historical Stock Prices
Graph 11.1 Millennium’s Historical Stock Prices Jan 2003 to Nov 2003
11.7 Key Financial Information
11.7.1 Revenue Under Strategic Alliance
Graph 11.2 Millennium’s Revenue Under Strategic Alliances 1998-2002
11.7.2 Total Revenues
Graph 11.3 Millennium’s Total Revenues 1998-2002
11.7.3 Total Operating Expenses
Graph 11.4 Millennium’s Total Costs and Expenses 1998-2002
11.7.4 Research and Development Expenses
Graph 11.5 Millennium’s Research and Development Expenses 1998-2002
11.7.5 Assets
Graph 11.6 Millennium’s Total Assets 1998-2002
11.7.6 Net Income (Loss)
Graph 11.7 Millennium’s Net Income (Loss) 1998-2002
11.7.7 Stockholders' Equity
Graph 11.8 Millennium’s Stockholders’ Equity 1998-2002
11.7.8 Earnings/Loss per Share
Graph 11.9 Millennium’s Total Income (Loss) per Share 1998-2002
11.8 Millennium's Key Businesses
11.8.1 Cardiovascular Diseases
11.8.2 Oncology
11.8.3 Inflammatory Disease
11.9 Integrilin: Millennium's First Major Product
11.9.1 Revenues
11.10 Velcade: New to the Cancer Market
11.11 Joint Ventures/Alliances
11.12 Research and Development
Table 11.1 Millennium’s Cardiovascular Pipeline
Table 11.2 Millennium’s Oncology Pipeline
Table 11.3 Millennium’s Inflammatory Pipeline
11.12.1 Highlights
11.13 Reasons for Success
~ PRICING ~
Individual report pricing - single user copies of this report are available
for only GBP£1499
Report pricing - departmental copies (this entitles up to 5 individual users
in your department) of this report are available for only GBP£2999
Allow your whole company to have access to this information for only
GBP£4499. Company-wide License allows your whole company access and intranet
use on CD Rom and .pdf.
Carriage is via Fedex:
USA - GBP£19.00; ASIA - GBP£25.00; Australia & NZ - GBP£25.00; EU GBP£23.00;
Rest of Europe GBP£27.00
UK is sent next day delivery through Royal Mail.
~ ORDERING ~
Ordering is simple! All you need to do is contact Althea James
mailto:althea.james!^!visiongaingroup.com
Please feel free to contact me should you have any questions, or want to buy
a copy.
Kind Regards
Althea James
Project Planner
visiongain
Tel: +44 (0)20 8767 6711
Fax: +44 (0)20 8767 5001
e-mail : mailto:althea.james~~visiongaingroup.com
visiongain produce a range of timely business information material, if you
wish to receive information of new products, simply reply to this email with
' New Products info' in the subject box.
By replying to this e-mail submitting your order for this product you have
agreed without limitation or qualification to be bound by and to comply with
these Terms and Conditions. You agree that you will not fail to complete any
transaction after submitting an order to purchase a product or submit any
order to purchase a product where you do not intend to complete the
transaction. You expressly acknowledge and agree that visiongain Ltd can
withhold any product as a result of non-payment within the agreed credit
terms of 30 days. Management Reports will only be sent on receipt of
payment. Confirm any cancellations, prior to payment, in writing within one
week and receive a refund less a 10% + VAT service charge. Regrettably, no
refunds can be made for cancellations after one week.
To unsubscribe please reply with unsubscribe in the subject line.
Data protection: Visiongain Ltd gathers and manages data in accordance with
the Data Protection Act 1998. Information contained about you may be used to
update you on visiongain Ltd products and services via post, telephone, fax
or email, unless you state otherwise. If you wish your details to be
amended, please send your request to the Database Manager, visiongain Ltd,
40 Tooting High Street, London, SW17 0RG. Alternatively please reply with
unsubscribe in the subject line. Please allow approximately 7 days for your
removal or update request, you may receive additional pieces of
communication from visiongain Ltd during the transitional period, whilst the
changes come into effect.
Received on 2001-10-14 - 00:34 GMT
This archive was generated by hypermail 2.2.0 : 2005-11-24 - 10:21 GMT